PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Rhea-AI Summary

PolyPid (NASDAQ: PYPD), a late-stage biopharma company focused on improving surgical outcomes, will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8-9, 2025, at the Lotte New York Palace Hotel in New York City.

The company's management will engage in a fireside chat with H.C. Wainwright Managing Director Brandon Folkes on Monday, September 8, from 11:30 AM to 12:00 PM ET. Additionally, the management team will be available for one-on-one meetings with investors, which can be arranged through H.C. Wainwright representatives or via meetings@hcwco.com.

News Market Reaction – PYPD

+0.29%

1 alert

+0.29% News Effect

+$156K Valuation Impact

$54M Market Cap

0.6x Rel. Volume

On the day this news was published, PYPD gained 0.29%, reflecting a mild positive market reaction. This price movement added approximately $156K to the company's valuation, bringing the market cap to $54M at that time.

Data tracked by StockTitan Argus on the day of publication.

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27^th Annual H.C. Wainwright Global Investment Conference taking place on September 8-9, 2025, at the Lotte New York Palace Hotel, New York City.

PolyPid's fireside chat with H.C. Wainwright Managing Director, Equity Research, Brandon Folkes, will take place from 11:30 AM - 12:00 PM ET on Monday, September 8, 2025.

The PolyPid management team will participate in virtual and in-person one-on-one investor meetings during this event. Investors attending the event may request a one-on-one meeting with PolyPid through their H.C. Wainwright representative or e-mail meetings@hcwco.com.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics,  PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX₁₀₀, PolyPid's lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd. 
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor & IR Contact:
Arx | Capital Markets
North American Equities Desk
polypid@arxadvisory.com

FAQ

When is PolyPid (PYPD) presenting at the H.C. Wainwright Conference 2025?

PolyPid will participate in a fireside chat on Monday, September 8, 2025, from 11:30 AM to 12:00 PM ET at the Lotte New York Palace Hotel in New York City.

How can investors schedule meetings with PolyPid management at the H.C. Wainwright Conference?

Investors can schedule one-on-one meetings with PolyPid management through their H.C. Wainwright representative or by emailing meetings@hcwco.com.

Where is the 2025 H.C. Wainwright Global Investment Conference being held?

The conference is being held at the Lotte New York Palace Hotel in New York City on September 8-9, 2025.

What type of company is PolyPid (PYPD)?

PolyPid is a late-stage biopharma company focused on improving surgical outcomes.